OBJECTIVE： To observe the efficacy and safety of prednisone combined with human immunoglobulin（pH4） for intravenous injection in the treatment of idiopathic thrombocytopenic purpura. METHODS： 85 patients with idiopathic thrombocytopenic purpura were divided into control group （42 cases） and observation group （43 cases）. Control group received 1.6 mg/（kg·d） Prednisone tablet， orally， for continuous 4 weeks； observation group received 400 mg/（kg·d） human immunoglobulin（pH4） for intravenous injection， intravenous injection， for continuous 5 d， then 1.6 mg/（kg·d） Prednisone tablet， orally， for continuous 4 weeks. All patients were given Adrenal color hydrazone tablet， Vitamin C tablet and other conventional treatment. Clinical efficacy， platelet number， T lymphocyte subsets （CD3+， CD3+CD4+， CD3+CD8+，CD19+），TNF-α， IL-6 before and after treatment， time of platelet number reached normal and reached peak value， peak value of platelet number and the incidence of adverse reactions in 2 groups were observed. RESULTS： The total effective rate and peak value of platelet number in observation group were significantly higher than control group， time of platelet number reached normal and reached peak value were significantly shorter than control group， the differences were statistically significant （P＜0.05）. Before treatment， there were no significant differences in platelet number， T lymphocyte subsets， IL-6 and TNF-α level in 2 groups （P＞0.05）； after treatment， platelet number， CD3+ and CD3+CD4+ in 2 groups were significantly higher than before， and observation group was higher than control group， IL-6， TNF-α level， CD3+CD8+ and CD19+ were significantly lower than before， and observation group was lower than control group， the differences were statistically significant （P＜0.05）. And there was no significant difference in the incidence of adverse reactions in 2 groups （P＞0.05）. CONCLUSIONS： Prednisone combined with human immunoglobulin（pH4）  for intravenous injection shows better efficacy than prednisone alone in the treatment of idiopathic thrombocytopenic purpura， it can increase platelet number， adjust immune function， and do not increase the incidence of adverse reactions.